Market Pulse: A federal judge’s halt of the Paramount–Warner Bros tie-up rippled through media stocks, while bank shares edged higher on earnings surprises.
Key Movers: The US court paused the Paramount–Warner deal (BBC News), and PNB shares jumped after a Q1 profit surge (The Times of India).
Macro & Politics: Twelve states led the antitrust suit that stalled Hollywood’s biggest merger bid, underscoring political pushback on consolidation.
What’s Next: Keep an eye on Calidi’s 1-for-16 reverse split kicking in on July 31 for split-adjusted trading.
Market Commentary
What everyone’s missing is that while Punjab National Bank’s shares ripped higher after a 214% Q1 profit surge, there’s a record pile of bearish bets on the S&P 500 (“Bearish bets on S&P 500 surge to record amid 18% rally,” Crypto Briefing). You’ve got retail euphoria from PSU lenders and hedge funds loading short collars against the broad market. When everyone’s piling on one side, that’s usually the trigger for a nasty squeeze. Don’t get caught leaning too hard on the rally without considering the squeeze risk lurking beneath those ominous short-interest figures.
It’s wild to see Eli Lilly plunk down $3.8 billion for AtaiBeckley (“Big Pharma And Psychedelic Medicine,” Forbes) while Harrow quietly showcases clinical wins for its ophthalmic gels at ASRS 2026 (“Harrow Highlights Growing Clinical Evidence,” GlobeNewswire). Investors either zero in on psychedelic therapeutics or niche eye treatments—yet both moves signal a broader shift: Big Pharma is chasing unique, high-margin disease areas. You can’t cherry-pick one hot theme; the real edge might come from the next overlooked pipeline beyond AI hype and blockbuster blockbusters.
Staking your claim now on stocks like IREN, which hiked its AI cloud revenue target above $4 billion (“IREN Stock Jumps 17%,” Ibtimes.com.au), feels sexy until the antitrust hammer drops. With the Paramount–Warner Bros. deal in limbo (BBC News) and regulators flexing muscle globally, any blockbuster merger can stall—or unravel overnight. Do yourself a favor: trim positions in headline-chasing plays, and allocate a slice to underappreciated names still flying below the radar.
📈 Breaking Financial News
Merger deal between Paramount and Warner Bros paused by judge
US court temporarily stops Paramount and Warner Bros merging after 12 states launched legal action.
PNB shares jump 7% in 2 days after Q1 earnings. Should you buy, sell or hold?
Punjab National Bank shares have surged in the last two sessions after the PSU lender reported a 214% year-on-year jump in Q1 FY27 net profit to Rs 5,253 crore, prompting bullish brokerage calls. Net interest income rose 2% to Rs 10,798 crore.
Sensex today | Stock Market Live: Stock to buy today: Home First Finance Company India (₹1,271) – BUY
Sensex Today, Nifty 50 | Stock Market Live Updates – Find here all the live updates related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 21st May 2026.
Jamie Dimon says markets underestimate risks and he wouldn't buy stocks or Treasurys at current prices – CNBC
Jamie Dimon says markets underestimate risks and he wouldn't buy stocks or Treasurys at current prices. CNBC notes JPMorgan poises to be the first $1 trillion bank amid his cautionary words.
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. will effect a reverse stock split on a 1-for-16 basis, adjusting its NYSE American listing ahead of July 31 trading.
[Urgent] Starlink Set For The Largest IPO In History?
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.
🔍 Market Analysis & Insights
Federal Judge Says Not So Fast to Paramount’s Takeover of Warner Bros. Discovery
“The Court is persuaded that it can presume the proposed merger is likely to violate antitrust laws,” wrote Judge Martínez-Olguín.
Jim Cramer says it may be time to trim comeback stock after 441% surge
I have watched Seagate's comeback story, and it has been one of the most impressive in the entire S&P 500. In fact, after the comeback, Seagate now ranks four…
Big Pharma And Psychedelic Medicine: Eli Lilly’s $3.8 Billion Bet
Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion marks a pivotal moment for psychedelic medicine.
IREN Stock Jumps 17% After Company Raises Its AI Cloud Revenue Target to Above $4 Billion for 2026
IREN Limited's stock surged 17% after the company raised its year-end revenue target to over $4 billion, driven by new multiyear AI cloud contracts, reversing a recent losing streak.
3 Numbers Show Wall Street Remains Blind About Meta’s AI Spend and Keep Me Loading Up
Wall Street keeps punishing Meta for its massive AI spending bill, but three specific numbers buried in the earnings data tell a completely different story a…
The Elon Musk “Mystery Metal” That Could Break China's Grip
Quietly engineered by Elon Musk… could end that crisis forever. And one tiny company is sitting at the center of it all. Musk is expected to make an announcement any day now. See more about this secret project here.
💰 Investment Opportunities
Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight
The degenerative disc disease market is witnessing a paradigm shift, transitioning from traditional symptom-focused treatments and surgical procedures toward regenerative and disease-modifying therapies. Emerging pipeline candidates, including SB-01 (Spine Bi…
Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight
The degenerative disc disease market is witnessing a paradigm shift, transitioning from traditional symptom-focused treatments and surgical procedures toward regenerative and disease-modifying therapies. Emerging pipeline candidates, including SB-01 (Spine Bi…
Why you should care about first new FDA-approved sunscreen ingredient in 20 years
Dermatologist says bemotrizinol, which has been available outside U.S. for decades, provides broader, longer lasting protection
Bearish bets on S&P 500 surge to record amid 18% rally
Short interest in S&P 500 stocks hits highest level since 2011 as hedge funds pile into bearish bets, even as the index keeps hitting all-time highs.
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) — Harrow highlights three studies supporting IHEEZO® (chloroprocaine HCl ophthalmic gel) and BYOOVIZ® in managing ophthalmic diseases.
Something doesn't add up. Jobs that “existed”… didn't in reality.
Jobs that existed… didn't in reality. The government deploying record AI spending. Yet Buffett holds $344B cash—his largest position EVER. Louis Navellier's grading system (46 years tracking money flows) reveals what the Wall Street elite see but won't tell you.